Abstract： Clinical studies have confirmed that severe or uncontrolled bronchial asthma (asthma)during pregnancy may result in adverse maternal and fetal outcomes. It is safer for pregnant women with asthma to be treated with asthma medications than for them to have asthma symptoms and exacerbations.Inhaled corticosteroids should be considered the controller medication for all severities of persistent asthma in pregnant women, preferably inhaled budesonide. Leukotrienes receptor antagonists protect against bronchoconstriction,reduce asthma symptoms and improve pulmonary function in patients with asthma.Long-acting β2-adrenergic agonists are the preferred adjunct to inhaled corticosteroids therapy in the pregnant patients with asthma. Inhaled short-acting β2-agonists are the rescue therapy. Continuation of allergen immunotherapy is recommended in patients who are at or near a maintenance dose, not experiencing adverse reactions to the therapy,and apparently deriving clinical benefit.